Skip to content

To check the skin irritation and safety of our product for Hair Oil, Skinovate Hair Shampoo, and Skinovate Hair Conditioner by a 24-hour in test in healthy human volunteers

To assess the primary skin irritation potential and safety of Skinovate Hair Oil, Skinovate Hair Shampoo, and Skinovate Hair Conditioner by a 24-hour occlusive patch test in healthy human volunteers - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/098150
Enrollment
24
Registered
2025-11-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Nil: Nil

Sponsors

Skinovate Laser Cosmetic Surgery Center
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Males and females aged eighteen to sixtyfive years 2 Healthy as determined by medical history and investigator exam 3 Intact skin at proposed application sites no cuts infections active dermatitis 4 Fitzpatrick skin types I VI accepted 5 Able and willing to provide written informed consent and comply with study procedures 6 Women of childbearing potential must use acceptable contraception and have a negative urine pregnancy test at screening

Exclusion criteria

Exclusion criteria: 1 Pregnant or lactating women. 2 Known hypersensitivity to any ingredient in the investigational products 3 History of atopic dermatitis, chronic eczema, psoriasis, or other active skin disease affecting the test area 4 Active acneiform or follicular infection at the intended application site 5 Use of systemic retinoids within previous 6 months or topical retinoids steroids at test site within 4 weeks 6Use of systemic immunosuppressive therapy or corticosteroids within 4 weeks 7 Known photosensitivity dermatographism or severe allergic history. 8 Participation in another interventional study or receipt of an investigational product within 30 days. 9 Recent within 3 weeks vaccination or intention to be vaccinated during study perio 10 Any condition which, in the investigators opinion would interfere with the safe conduct of the study or interpretation of results

Design outcomes

Primary

MeasureTime frame
Primary irritation as scored by the Draize scale erythema dryness wrinkling oedema recorded at Visit 2 24 h after occlusion removal and Visit 3 48 h after occlusion removal The maximum Draize score recorded per site will be used for analysisTimepoint: 24 hours and 48 hours

Secondary

MeasureTime frame
1 Incidence frequency & severity of AEs SAEs during the study period 2 Subject reported sensations at the test site non mild moderate severe for itching burning tinging Timepoint: 24 hours & 48 hours

Countries

India

Contacts

Public ContactDr Sonal Shendkar

Skinovate Laser Cosmetic Surgery Center,

drsonalshendkar2@gmail.com09743849130

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026